https://m2.mtmt.hu/ hun 2026-10-25 01:01 JournalArticle 32033801 VALIDATED true Cited By :4 Export Date: 5 May 2023 Correspondence Address: Hannoun-Levi, J.-M.; Radiation Oncology Department, 33 Avenue Valombrose, France; email: jean-michel.hannoun-levi@nice.unicancer.fr Chemicals/CAS: epidermal growth factor receptor 2, 137632-09-8; trastuzumab, 180288-69-1, 1446410-98-5 0 false 2026-10-21T09:12:39.512+0000 2021-09-22T07:07:27.031+0000 2021-05-25T07:24:04.477+0000 true 10070075 Nádas Orsolya /api/admin/10070075 Admin true 2025-07-22T06:24:00.533+0000 2021-05-27T09:45:23.616+0000 true 10015544 Csajbók Edit /api/admin/10015544 Admin true 10015544 2021-07-26T08:29:12.678+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin true 10062250 Admin 10067876 /api/admin/10067876 Ladányi Gusztáv true true Admin 10080105 /api/admin/10080105 Kériné Tornyi Katalin true true 2024-10-17T16:16:12.275+0000 true false true 24 24 /api/publicationtype/24 PublicationType 1 true 24 JournalArticle true 10000359 Study Group true 24 24 /api/publicationtype/24 PublicationType 1 true 24 JournalArticle /api/subtype/10000359 Sokszerzős vagy csoportos szerzőségű szakcikk SubType 104 true 10000359 true 1 /api/category/1 Category true 1 Hannoun-Levi, Jean-Michel Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early-stage breast cancer (EPOPE) The rationale for a GEC-ESTRO randomized phase III-controlled trial true true /api/journal/10087499 REVIEWED true false 10087499 false 10087499 true 2405-6308 Journal FOREIGN 29 1 8 1 8 2021 Breast cancer in the elderly has become a public health concern; there is a need to re-design its treatment with a view to de-escalation. Our paper sets out the rationale for a phase 3 randomized trial to evaluate less burdensome adjuvant procedures that remain effective and efficient.For low-risk breast cancer in the elderly, adjuvant treatment has been adjusted in order to make it more suitable and efficient. Hypofractionated radiation therapy based on accelerated or non-accelerated regimens as well as accelerated and ultra-accelerated partial breast irradiation (APBI) protocols were reviewed. Withdrawal of radiation (RT) or endocrine therapies (ET) from the adjuvant procedure were also investigated. Based on molecular and APBI classifications, inclusion criteria were discussed.Phase 3 randomized trials which compared standard vs. accelerated/non-accelerated hypofractionated regimens confirmed that the latter were non-inferior in terms of local control. Similarly, except for intraoperative-based techniques, APBI achieved non-inferior local control rates compared to whole breast irradiation for low-risk breast cancer. In phase 2 prospective trials using ultra APBI, encouraging results were observed regarding oncological outcome and toxicity profile. In phase 3 trials, adjuvant ET without RT significantly increased the rate of local relapse with no impact on overall survival while RT alone proved effective. Elderly patients aged 60 or more with low-risk, luminal A breast cancer were chosen as the target population in a phase 3 randomized trial comparing APBI + 5-year ET vs. uAPBI (16 Gy 1f) alone.To investigate de-escalation adjuvant treatment for elderly breast cancer patients, we have defined a road map for testing more convenient strategies. This EPOPE phase 3 randomized trial is supported by the GEC-ESTRO breast cancer working group. true 2021 true true true false true false GOLD 2026-10-21 true https://doi.org/10.1016/j.ctro.2021.04.005 16 0 15 13 1 16 15 14 14 15 15 13 13 14 2 0 16 14 15 13 0 6 6 Folyóiratcikk Journal Article 24 14 Könyvrészlet Chapter in Book 25 1 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 1 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 1 1 1 1 2023 0 5 5 5 5 2024 0 4 3 4 3 2025 0 3 3 3 3 2026 0 3 2 3 2 Q1 false false false false 2021-05-26T09:45:23.353+0000 Onkológiai Tanszék (SE / AOK / K) 1 6 1 5 0 true 10080105 10067876 Language 10002 /api/language/10002 Angol English true 2 true PersonAuthorship 96399861 /api/authorship/96399861 1 0.2 true false true Hannoun-Levi Jean-Michel true false false AuthorshipType 1 /api/authorshiptype/1 0 true 0 true false true OrgAuthorship 96399866 /api/authorship/96399866 2 0.0 false false false true false false AuthorshipType 30 /api/authorshiptype/30 -29 true -29 true false true PersonAuthorship 96399862 /api/authorship/96399862 2 0.2 false false false Chamorey Emmanuel true false false AuthorshipType 1 /api/authorshiptype/1 0 true 0 true false true PersonAuthorship 96399863 /api/authorship/96399863 3 0.2 false false false Boulahssass Rabia true false false AuthorshipType 1 /api/authorshiptype/1 0 true 0 true false true PersonAuthorship 96399864 /api/authorship/96399864 4 0.2 false false false Author 10013383 /api/author/10013383 Polgár Csaba true 10013383 true Polgar Csaba true false false AuthorshipType 1 /api/authorshiptype/1 0 true 0 true false true PersonAuthorship 96399865 /api/authorship/96399865 5 0.2 false true false Strnad Vratislav true false false AuthorshipType 1 /api/authorshiptype/1 0 true 0 true false true PublicationIdentifier 18831956 /api/publicationidentifier/18831956 PlainSource 6 /api/publicationsource/6 PublicationSourceType 10001 /api/publicationsourcetype/10001 true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.ctro.2021.04.005 https://doi.org/10.1016/j.ctro.2021.04.005 false true PublicationIdentifier 19025460 /api/publicationidentifier/19025460 PlainSource 1 /api/publicationsource/1 PublicationSourceType 10003 /api/publicationsourcetype/10003 false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000668240600001 https://www.webofscience.com/wos/woscc/full-record/000668240600001 false true PublicationIdentifier 19346253 /api/publicationidentifier/19346253 PlainSource 3 /api/publicationsource/3 PublicationSourceType 10003 /api/publicationsourcetype/10003 false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85114753608 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85114753608 false true PublicationIdentifier 18831955 /api/publicationidentifier/18831955 PlainSource 17 /api/publicationsource/17 PublicationSourceType 10003 /api/publicationsourcetype/10003 false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33997321 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33997321&dopt=Abstract false true Keyword 19325 /api/keyword/19325 true 19325 true Keyword 19760 /api/keyword/19760 true 19760 true Keyword 1077876 /api/keyword/1077876 true 1077876 true Keyword 1326338 /api/keyword/1326338 true 1326338 true Keyword 2313603 /api/keyword/2313603 true true Keyword 2313604 /api/keyword/2313604 true true Keyword 2313605 /api/keyword/2313605 true true Keyword 2313606 /api/keyword/2313606 true true Keyword 2313607 /api/keyword/2313607 true true Keyword 2313608 /api/keyword/2313608 true true Keyword 2313609 /api/keyword/2313609 true true Keyword 2313610 /api/keyword/2313610 true true Keyword 2313611 /api/keyword/2313611 true true Keyword 2313612 /api/keyword/2313612 true true Keyword 2313613 /api/keyword/2313613 true true Keyword 2313614 /api/keyword/2313614 true true Keyword 2313615 /api/keyword/2313615 true true Keyword 2313616 /api/keyword/2313616 true true Keyword 2313617 /api/keyword/2313617 true true Keyword 2313618 /api/keyword/2313618 true true Keyword 2313619 /api/keyword/2313619 true true Keyword 2313620 /api/keyword/2313620 true true Keyword 2313621 /api/keyword/2313621 true true Keyword 2313622 /api/keyword/2313622 true true SjrRating 11231632 /api/sjrrating/11231632 70 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr true true ClassificationExternal 2730 /api/classificationexternal/2730 true 2730 true Q1 DIRECT true true /api/publication/32033801 <div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Hannoun-Levi Jean-Michel ✉ </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Chamorey Emmanuel </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Boulahssass Rabia </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013383"><a href="/gui2/?type=authors&mode=browse&sel=10013383" target="_blank">Polgar Csaba (<span class="authorship-author-name">Polgár Csaba</span> <span class="authorAux-mtmt"> Sugárterápia, klinikai onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Onkológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Strnad Vratislav<sup>**</sup> </span> </div> <div class="autype autype-29"> Kollaborációs szervezet: <span class="author-affil">Breast Cancer Working Group of the GEC-ESTRO</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32033801" target="_blank">Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early-stage breast cancer (EPOPE) : The rationale for a GEC-ESTRO randomized phase III-controlled trial.</a></div> <div> <span class="journal-title">CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2405-6308">2405-6308</a>)</span>: <span class="journal-volume">29</span> <span class="page"> pp 1-8 </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.ctro.2021.04.005" target="_blank" href="https://doi.org/10.1016/j.ctro.2021.04.005"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000668240600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000668240600001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85114753608" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85114753608"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33997321" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33997321&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Radiology, Nuclear Medicine and Imaging&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 16</span> | Független: 14 | Függő: 2 | Nem jelölt: 0 | WoS jelölt: 14 | Scopus jelölt:&nbsp;14 | WoS/Scopus jelölt:&nbsp;15 | DOI jelölt:&nbsp;15 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32033801&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 6 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32033801</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Sokszerzős vagy csoportos szerzőségű szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2021.09.22. 09:07 Sághi-Keszthelyi Anna (SE_KK_Admin5_SKA, admin) </div> <div class="lockedBy">Központi kezelésű 2024.10.17. 18:16 Ladányi Gusztáv (MTMT API user, admin) Kériné Tornyi Katalin (MTMT ellenőrzés admin5) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Cited By :4 Export Date: 5 May 2023 Correspondence Address: Hannoun-Levi, J.-M.; Radiation Oncology Department, 33 Avenue Valombrose, France; email: jean-michel.hannoun-levi@nice.unicancer.fr Chemicals/CAS: epidermal growth factor receptor 2, 137632-09-8; trastuzumab, 180288-69-1, 1446410-98-5</pre> </div></div>